GLP-1RAと低死亡率,心血管疾患および精神疾患のリスク:大規模なコホート研究
Henning Olbrich1, Khalaf Kridin2,3,4, Henner Zirpel5
1Department of Dermatology, Allergy, and Venerology, University of Lübeck, Lübeck, Germany.
The British journal of dermatology
|September 2, 2025
まとめ
グルカゴン類ペプチド-1受容体アゴニスト (GLP- 1RA) は,肥満または糖尿病の牛皮病患者の死亡率と心血管疾患のリスクを有意に低下させた. この安全な治療法では精神疾患の併発リスクも低下し,牛皮の患者ではより大きな効果が見られた.
科学分野:
- 皮膚科
- 心臓病科
- 内分泌学
背景:
- 牛皮病は重度の心血管と代謝の問題と関連しています
- グルカゴン類ペプチド-1受容体アゴニスト (GLP- 1RA) は肥満と糖尿病の治療に使用され,牛皮の患者に有益である可能性があります.
研究 の 目的:
- GLP- 1RAの死亡率,心血管,炎症,精神疾患に対する効果を評価する.
- この集団におけるGLP- 1RAに関連する有害事象を評価する.
主な方法:
- 米国TrinetXデータを用いた人口ベースコホート研究.
- GLP- 1RAを投与された患者と他の治療を投与された患者を,傾向スコアを合わせた後,3, 048人を比較した.
- 分析された心代謝,精神疾患,自己免疫的アウトカム,死亡率,有害事象.
主要な成果:
- GLP- 1RAの使用は,すべての原因による死亡率 (HR 0. 219) と重篤な不良心疾患 (MACE) (HR 0. 561) を有意に低下させた.
- アルコールや薬物乱用のリスクは減少した.
- 典型的な有害事象の増加は認められず,リスクの減少は,非症のコホートよりも大きい.
結論:
- GLP- 1RA治療は肥満や糖尿病の患者にとって安全です.
- GLP- 1RAは,心血管疾患と精神疾患の併発リスクと死亡率を著しく低下させる.
- 併発性肥満や糖尿病の患者では,GLP- 1RAを考慮する必要があります.
関連する概念動画
Glucagon-like Receptor Agonists
416
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
416
Dipeptidyl Peptidase 4 Inhibitors
252
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
252
Psychoneuroimmunology: Cardiovascular Disease
77
Psychoneuroimmunology (PNI) is a multidisciplinary field that examines how psychological factors, particularly stress, interact with the immune system and impact physical health. Research in PNI has shown that chronic or traumatic stress can disrupt both the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. These disruptions contribute to serious health conditions, including cardiovascular diseases.
A key area of focus in PNI is the relationship between stress and coronary...
A key area of focus in PNI is the relationship between stress and coronary...
77
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
251
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
251
Oral Hypoglycemic Agents: Biguanides and Glitazones
288
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
288
GPCRs Regulate Adenylyl Cylase Activity
5.9K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
5.9K


